Before You Begin
Question #47407
The Question
A 45-year-old female presents with severe, symmetrical inflammation of the synovial membranes in her hinge joints. Her physician prescribes a bioactive molecule commercially produced by the fungus Trichoderma polysporum. Which of the following best describes the primary rationale for using this specific molecule to manage her joint pathology?
Options
- A.
It acts as a systemic immunosuppressant by inhibiting T-cell activation, thereby halting the cell-mediated autoimmune destruction of the synovial tissue.
- B.
It inhibits the synthesis of prostaglandins by blocking cyclooxygenase enzymes, directly reducing pain and swelling in the synovial cavity.
- C.
It prevents the deposition of uric acid crystals in the synovial fluid by inhibiting purine metabolism.
- D.
It acts as a statin to competitively inhibit cholesterol synthesis, which indirectly reduces the inflammatory markers in the synovial fluid.
Check Your Answer
Correct Answer
Step-by-Step Solution
Explanation
How the Examiner Thinks
Regulatory_Failure
Understand how NOT, EXCEPT, and logical constraints are used to manipulate exam results.
Concepts Behind This Question
Synovial_Joint_Varieties|Cyclosporin_A_Immunomodulation|Autoimmunity_Principles
Why This Question Is Tricky
Common Mistakes
Conceptual Pivot: Cross-chapter synthesis between 'Microbes in Human Welfare' (Cyclosporin A) and 'Locomotion and Movement' / 'Human Health and Disease' (Rheumatoid Arthritis).
Students often compartmentalize Cyclosporin A strictly for 'organ transplants' and fail to recognize its application in suppressing T-cell mediated autoimmune destruction of synovial joints, often falling for the 'uric acid' or 'prostaglandin' traps associated with other types of arthritis.
Quick Facts About This Question
Question Information
| Subject | Biology |
| Chapter | Locomotion and Movement - Class 11 |
| Concept | Synovial Joint Varieties |
| Difficulty | 8 |
| Cognitive Load | 5 |
| Target Solve Time | 120 sec |
| Access | Free |